These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
479 related articles for article (PubMed ID: 37863727)
1. Multiparametric Magnetic Resonance Imaging in Prostate Cancer Screening at the Age of 45 Years: Results from the First Screening Round of the PROBASE Trial. Boschheidgen M; Albers P; Schlemmer HP; Hellms S; Bonekamp D; Sauter A; Hadaschik B; Krilaviciute A; Radtke JP; Seibold P; Lakes J; Arsov C; Gschwend JE; Herkommer K; Makowski M; Kuczyk MA; Wacker F; Harke N; Debus J; Körber SA; Benner A; Kristiansen G; Giesel FL; Antoch G; Kaaks R; Becker N; Schimmöller L Eur Urol; 2024 Feb; 85(2):105-111. PubMed ID: 37863727 [TBL] [Abstract][Full Text] [Related]
2. Diagnostic Accuracy of Single-plane Biparametric and Multiparametric Magnetic Resonance Imaging in Prostate Cancer: A Randomized Noninferiority Trial in Biopsy-naïve Men. Russo F; Mazzetti S; Regge D; Ambrosini I; Giannini V; Manfredi M; De Luca S; Bollito E; Porpiglia F Eur Urol Oncol; 2021 Dec; 4(6):855-862. PubMed ID: 33893066 [TBL] [Abstract][Full Text] [Related]
3. Comparison of Biparametric and Multiparametric MRI for Clinically Significant Prostate Cancer Detection With PI-RADS Version 2.1. Tamada T; Kido A; Yamamoto A; Takeuchi M; Miyaji Y; Moriya T; Sone T J Magn Reson Imaging; 2021 Jan; 53(1):283-291. PubMed ID: 32614123 [TBL] [Abstract][Full Text] [Related]
4. Combined Clinical Parameters and Multiparametric Magnetic Resonance Imaging for Advanced Risk Modeling of Prostate Cancer-Patient-tailored Risk Stratification Can Reduce Unnecessary Biopsies. Radtke JP; Wiesenfarth M; Kesch C; Freitag MT; Alt CD; Celik K; Distler F; Roth W; Wieczorek K; Stock C; Duensing S; Roethke MC; Teber D; Schlemmer HP; Hohenfellner M; Bonekamp D; Hadaschik BA Eur Urol; 2017 Dec; 72(6):888-896. PubMed ID: 28400169 [TBL] [Abstract][Full Text] [Related]
5. Prostate Cancer Screening with Magnetic Resonance Imaging: Results from the Second Round of the Göteborg Prostate Cancer Screening 2 Trial. Wallström J; Geterud K; Kohestani K; Maier SE; Pihl CG; Socratous A; Stranne J; Arnsrud-Godtman R; Månsson M; Hellström M; Hugosson J Eur Urol Oncol; 2022 Feb; 5(1):54-60. PubMed ID: 34580053 [TBL] [Abstract][Full Text] [Related]
6. Detection of Clinically Significant Prostate Cancer Using Targeted Biopsy with Four Cores Versus Target Saturation Biopsy with Nine Cores in Transperineal Prostate Fusion Biopsy: A Prospective Randomized Trial. Saner YM; Wiesenfarth M; Weru V; Ladyzhensky B; Tschirdewahn S; Püllen L; Bonekamp D; Reis H; Krafft U; Heß J; Kesch C; Darr C; Forsting M; Wetter A; Umutlu L; Haubold J; Hadaschik B; Radtke JP Eur Urol Oncol; 2023 Feb; 6(1):49-55. PubMed ID: 36175281 [TBL] [Abstract][Full Text] [Related]
7. Multicentre evaluation of targeted and systematic biopsies using magnetic resonance and ultrasound image-fusion guided transperineal prostate biopsy in patients with a previous negative biopsy. Hansen NL; Kesch C; Barrett T; Koo B; Radtke JP; Bonekamp D; Schlemmer HP; Warren AY; Wieczorek K; Hohenfellner M; Kastner C; Hadaschik B BJU Int; 2017 Nov; 120(5):631-638. PubMed ID: 27862869 [TBL] [Abstract][Full Text] [Related]
8. Head-to-head Comparison of Transrectal Ultrasound-guided Prostate Biopsy Versus Multiparametric Prostate Resonance Imaging with Subsequent Magnetic Resonance-guided Biopsy in Biopsy-naïve Men with Elevated Prostate-specific Antigen: A Large Prospective Multicenter Clinical Study. van der Leest M; Cornel E; Israël B; Hendriks R; Padhani AR; Hoogenboom M; Zamecnik P; Bakker D; Setiasti AY; Veltman J; van den Hout H; van der Lelij H; van Oort I; Klaver S; Debruyne F; Sedelaar M; Hannink G; Rovers M; Hulsbergen-van de Kaa C; Barentsz JO Eur Urol; 2019 Apr; 75(4):570-578. PubMed ID: 30477981 [TBL] [Abstract][Full Text] [Related]
9. Results from the PRIMA Trial: Comparison of the STHLM3 Test and Prostate-specific Antigen in General Practice for Detection of Prostate Cancer in a Biopsy-naïve Population. Fredsøe J; Sandahl M; Vedsted P; Jensen JB; Ulhøi BP; Borre M; Sørensen KD; Pedersen BG; Eur Urol Oncol; 2023 Oct; 6(5):484-492. PubMed ID: 37537016 [TBL] [Abstract][Full Text] [Related]
10. Multiparametric Magnetic Resonance Imaging Second Opinion May Reduce the Number of Unnecessary Prostate Biopsies: Time to Improve Radiologists' Training Program? Luzzago S; Petralia G; Musi G; Catellani M; Alessi S; Di Trapani E; Mistretta FA; Serino A; Conti A; Pricolo P; Nazzani S; Mirone V; Matei DV; Montanari E; de Cobelli O Clin Genitourin Cancer; 2019 Apr; 17(2):88-96. PubMed ID: 30527286 [TBL] [Abstract][Full Text] [Related]
11. Head-to-head comparison of biparametric versus multiparametric MRI of the prostate before robot-assisted transperineal fusion prostate biopsy. Thaiss WM; Moser S; Hepp T; Kruck S; Rausch S; Scharpf M; Nikolaou K; Stenzl A; Bedke J; Kaufmann S World J Urol; 2022 Oct; 40(10):2431-2438. PubMed ID: 35922717 [TBL] [Abstract][Full Text] [Related]
12. The "Is mpMRI Enough" or IMRIE Study: A Multicentre Evaluation of Prebiopsy Multiparametric Magnetic Resonance Imaging Compared with Biopsy. Stonier T; Simson N; Shah T; Lobo N; Amer T; Lee SM; Bass E; Chau E; Grey A; McCartan N; Acher P; Ahmad I; Arumainayagam N; Brown D; Chapman A; Elf D; Hartington T; Ibrahim I; Leung H; Liyanage S; Lovegrove C; Malthouse T; Mateen B; Mistry K; Morrison I; Nalagatla S; Persad R; Pope A; Sokhi H; Syed H; Tadtayev S; Tharmaratnam M; Qteishat A; Miah S; Emberton M; Moore C; Walton T; Eddy B; Ahmed HU Eur Urol Focus; 2021 Sep; 7(5):1027-1034. PubMed ID: 33046412 [TBL] [Abstract][Full Text] [Related]
13. A Multicentre Analysis of the Detection of Clinically Significant Prostate Cancer Following Transperineal Image-fusion Targeted and Nontargeted Systematic Prostate Biopsy in Men at Risk. Miah S; Hosking-Jervis F; Connor MJ; Eldred-Evans D; Shah TT; Arya M; Barber N; Bhardwa J; Bott S; Burke D; Doherty A; Foster C; Freeman A; Hindley R; Jameson C; Karim O; Laniado M; Montgomery B; Nigam R; Punwani S; Sinclair A; Winkler M; Allen C; Ahmed HU Eur Urol Oncol; 2020 Jun; 3(3):262-269. PubMed ID: 31411968 [TBL] [Abstract][Full Text] [Related]
14. Prostate cancer gene 3 (PCA3) is of additional predictive value in patients with PI-RADS grade III (intermediate) lesions in the MR-guided re-biopsy setting for prostate cancer. Kaufmann S; Bedke J; Gatidis S; Hennenlotter J; Kramer U; Notohamiprodjo M; Nikolaou K; Stenzl A; Kruck S World J Urol; 2016 Apr; 34(4):509-15. PubMed ID: 26267808 [TBL] [Abstract][Full Text] [Related]
15. Prediction of High-grade Prostate Cancer Following Multiparametric Magnetic Resonance Imaging: Improving the Rotterdam European Randomized Study of Screening for Prostate Cancer Risk Calculators. Alberts AR; Roobol MJ; Verbeek JFM; Schoots IG; Chiu PK; Osses DF; Tijsterman JD; Beerlage HP; Mannaerts CK; Schimmöller L; Albers P; Arsov C Eur Urol; 2019 Feb; 75(2):310-318. PubMed ID: 30082150 [TBL] [Abstract][Full Text] [Related]
16. Reproducibility and Accuracy of the PRIMARY Score on PSMA PET and of PI-RADS on Multiparametric MRI for Prostate Cancer Diagnosis Within a Real-World Database. Emmett L; Papa N; Counter W; Calais J; Barbato F; Burger I; Eiber M; Roberts MJ; Agrawal S; Franklin A; Xue A; Rasiah K; John N; Moon D; Frydenberg M; Yaxley J; Stricker P; Wong K; Coughlin G; Gianduzzo T; Kua B; Ho B; Nguyen A; Liu V; Lee J; Hsiao E; Sutherland T; Perry E; Fendler WP; Hope TA J Nucl Med; 2024 Jan; 65(1):94-99. PubMed ID: 38050155 [TBL] [Abstract][Full Text] [Related]
17. Magnetic Resonance Imaging-guided Active Surveillance Without Annual Rebiopsy in Patients with Grade Group 1 or 2 Prostate Cancer: The Prospective PROMM-AS Study. Valentin B; Arsov C; Ullrich T; Al-Monajjed R; Boschheidgen M; Hadaschik BA; Giganti F; Giessing M; Lopez-Cotarelo C; Esposito I; Antoch G; Albers P; Radtke JP; Schimmöller L Eur Urol Open Sci; 2024 Jan; 59():30-38. PubMed ID: 38298772 [TBL] [Abstract][Full Text] [Related]
18. The Additive Diagnostic Value of Prostate-specific Membrane Antigen Positron Emission Tomography Computed Tomography to Multiparametric Magnetic Resonance Imaging Triage in the Diagnosis of Prostate Cancer (PRIMARY): A Prospective Multicentre Study. Emmett L; Buteau J; Papa N; Moon D; Thompson J; Roberts MJ; Rasiah K; Pattison DA; Yaxley J; Thomas P; Hutton AC; Agrawal S; Amin A; Blazevski A; Chalasani V; Ho B; Nguyen A; Liu V; Lee J; Sheehan-Dare G; Kooner R; Coughlin G; Chan L; Cusick T; Namdarian B; Kapoor J; Alghazo O; Woo HH; Lawrentschuk N; Murphy D; Hofman MS; Stricker P Eur Urol; 2021 Dec; 80(6):682-689. PubMed ID: 34465492 [TBL] [Abstract][Full Text] [Related]
19. Targeted multiparametric magnetic resonance imaging/transrectal ultrasound-guided (mpMRI/TRUS) fusion prostate biopsy versus systematic random prostate biopsy: A comparative real-life study. Pham THN; Schulze-Hagen MF; Rahnama'i MS Cancer Rep (Hoboken); 2024 Feb; 7(2):e1962. PubMed ID: 38217298 [TBL] [Abstract][Full Text] [Related]
20. Association Between Prostate Imaging Reporting and Data System (PI-RADS) Score for the Index Lesion and Multifocal, Clinically Significant Prostate Cancer. Stabile A; Dell'Oglio P; De Cobelli F; Esposito A; Gandaglia G; Fossati N; Brembilla G; Cristel G; Cardone G; Deho' F; Losa A; Suardi N; Gaboardi F; Del Maschio A; Montorsi F; Briganti A Eur Urol Oncol; 2018 May; 1(1):29-36. PubMed ID: 31100225 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]